CPC C12N 15/86 (2013.01) [A61K 38/465 (2013.01); A61K 48/005 (2013.01); A61K 48/0058 (2013.01); A61P 1/16 (2018.01); A61P 25/28 (2018.01); A61P 35/04 (2018.01); C07K 14/005 (2013.01); C12N 9/22 (2013.01); C12Q 1/68 (2013.01); G01N 33/5308 (2013.01); A01K 2207/12 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); A61B 5/4848 (2013.01); A61B 2017/00893 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14145 (2013.01); C12N 2830/008 (2013.01); G01N 2333/435 (2013.01); G01N 2800/7028 (2013.01)] | 6 Claims |
1. A method for inhibiting growth of a primary tumor in a subject having a cancer accompanied by accumulation of cell free DNA (cfDNA) in the hepatic porto-sinusoidal circulation of the subject, said method comprising administering to the subject a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) expression vector comprising (i) a capsid protein and (ii) a nucleic acid comprising a promoter operably linked to a nucleotide sequence encoding an enzyme which has a deoxyribonuclease (DNase) activity, wherein the promoter is a liver-specific promoter, wherein the nucleic acid comprises the sequence of SEQ ID NO: 30 or SEQ ID NO: 31, and wherein the administration of the rAAV vector results in inhibiting growth of the primary tumor in the subject.
|